To investigate the prognostic effect of CD86+/CD206+ TAMs model in CA-199 negative patients (cut-off value 36 U/ml) (Chen et al., 2015), 163 patients from the 322 ICC patient cohort were enrolled. The gene discussed is CD86; the disease is intrahepatic cholangiocarcinoma.